Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) – William Blair lowered their Q3 2017 EPS estimates for Adamas Pharmaceuticals in a research report issued on Wednesday. William Blair analyst T. Lugo now anticipates that the specialty pharmaceutical company will earn ($1.03) per share for the quarter, down from their previous forecast of ($0.96). William Blair also issued estimates for Adamas Pharmaceuticals’ Q4 2017 earnings at ($1.17) EPS, FY2017 earnings at ($3.85) EPS and FY2018 earnings at ($1.32) EPS.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the prior year, the firm earned ($0.78) EPS. Adamas Pharmaceuticals’s revenue for the quarter was down 90.9% compared to the same quarter last year. COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/william-blair-weighs-in-on-adamas-pharmaceuticals-inc-s-q3-2017-earnings-adms.html.

A number of other research analysts have also issued reports on the company. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday. Cowen and Company set a $45.00 target price on Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday. BidaskClub lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, Mizuho reiterated a “buy” rating and set a $26.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Adamas Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $29.00.

Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 15.25 on Friday. The stock has a 50 day moving average of $17.28 and a 200 day moving average of $16.85. The stock’s market cap is $343.34 million. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $19.50.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. American International Group Inc. raised its position in shares of Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 682 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 3,358 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Adamas Pharmaceuticals during the first quarter worth $287,000. Alps Advisors Inc. raised its position in shares of Adamas Pharmaceuticals by 6.7% in the second quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock worth $353,000 after buying an additional 1,272 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Adamas Pharmaceuticals during the fourth quarter worth $469,000. Institutional investors own 71.33% of the company’s stock.

In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of the firm’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $17.05, for a total value of $5,967,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 731,041 shares of company stock worth $12,476,149 in the last 90 days. 29.00% of the stock is currently owned by insiders.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.